Genexine, Inc.

Genexine, Inc. is a dynamic biotechnology company dedicated to saving lives through innovative research and development. Headquartered in Gangseo-gu, Seoul-si, at 172, Magokjungang-ro, Bio innovation park, Genexine is focused on developing and commercializing cutting-edge immunotherapeutics and next-generation technologies. With a commitment to the well-being and care of patients worldwide, Genexine is making significant strides in the field of biotechnology.

Genexine's primary technology platforms include Therapeutic DNA vaccine and hyFc® long-acting technology, as well as the innovative bioPROTAC platform. The company boasts a robust pipeline of products in clinical development, including several undergoing Phase 3 registrational trials. Among these are GX-188E (tirvalimogene teraplasmid) for head and neck cancer and cervical cancer, GX-I7 (efineptakin alfa) for multiple solid cancers and ARS, GX-H9 (eftansomatropin alfa) for Pediatric Growth Hormone Deficiency, and GX-E4 for CKD-induced anemia.

Listed on the Korean exchange (KOSDAQ: 095700), Genexine has established multiple strategic partnerships with global companies to expedite product development and commercialization, creating substantial value in the process. Genexine continues to push the boundaries of biotechnology, with a vision of improving patient outcomes and advancing medical science. We invite the management team at Genexine, Inc. to create a customized and exclusive company showcase and product listing on our platform to further amplify their reach and impact.